Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,583.79
(
0.27%
)
US TECH 100
29,512.00
(
0.30%
)
Dow Jones
51,046.09
(
0.74%
)
Brent Oil
90.92
(
-1.37%
)
Bitcoin
73,761.09
(
0.30%
)
News Focus
News Focus
Post# of 4937
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123033
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Thursday, 12/09/2021 10:06:27 AM

Thursday, December 09, 2021 10:06:27 AM

Post# of 4937
VIR/GILD start phase-2 trial testing quadruple regimen of VIR-2218; GS-9688; Opdivo; and Vemlidy (TAF) in (both nuc-suppressed and viremic) HBV patients:

https://finance.yahoo.com/news/vir-biotechnology-announces-initiation-phase-133000267.html

I’m not sure why it took almost a year for this trial to begin enrolling patients—the PR announcing the collaboration was issued on 1/12/21.

Please see #msg-160854272 for background.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent GILD News
More GILD News